You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

February 22, 2012

IP Holding Vehicles: Singapore vs. Hong Kong

Informed Counsel

With intellectual property playing an ever-increasing role in economic development, the need to harness, promote, and protect ASEAN innovation has become more urgent as integration progresses. Among its objectives, the AEC aims to transform the region into a hub of innovation and competitiveness and ensure that the region remains an active participant in the international IP community. With ASEAN member states gearing up toward increased IP generation and with further commitments to global IP regimes, the region may soon look to sophisticated IP ownership and holding structures.

IP Holding Companies

Recognizing the importance of securing IP rights in the upcoming era of AEC, a trend has developed among ASEAN-based companies to centralize ownership of their IP assets in offshore holding and licensing vehicles—an approach multinational companies have been using for a number of years. IP-intensive companies look to locate their IP portfolios in low-tax jurisdictions with strong IP registration and protection laws. The company then licenses the IP to operating companies in the group or to third party licensees, franchisees, agents, distributors, etc. in return for royalties or license fees. These special-purpose vehicles are typically referred to as IP Holding Companies.

IP Holding Companies are popular because they can help corporations to minimize tax, gain tax benefits/concessions, protect IP from bankruptcy or other claims against the parent company, and focus management attention on the IP portfolio in order to see it as an income generator.

Tax and Deciding on Your IP Holding Company

Tax is the primary reason most companies park their IP in separate IP holding vehicles. Sometimes, companies select a no-tax, low-tax, or preferred-tax jurisdiction in which to establish their IP Holding Company that is close to their home country.

The selected jurisdiction should also be a country with a large and well-established tax treaty network. Double tax treaties are key criteria in jurisdiction shopping. If the IP assets need to be pledged as a security for future borrowings or if they are to be included in the parent company’s asset sheets prior to a public listing, having those IP assets in a respected, transparent country is always beneficial. Also, depending on whether any R&D might be planned, many countries have attractive tax benefits for such activities as a way to encourage local innovation and technology transfer into the country. If the parent has other business operations in the selected country, it very well may be that such items as development or operational costs, company losses in respect of certain activities, or amortization schemes may be available to offset against profit-generating activities.

Singapore

In the past few years, Singapore has emerged as one of the most IP-focused jurisdictions in Asia, with the government going to great lengths to encourage the transfer of technology and IP to the country. Generally, the IP tax incentives offered in Singapore apply to a wide range of qualifying expenditure incurred on qualifying activities, such as R&D done in Singapore (with additional possible deductions on some R&D done outside Singapore), registration of IP rights, acquisition of IP rights, investments in automation, training of employees, and investments in design done in Singapore.

One of the main factors why Singapore is fast becoming Asia’s go-to place to hold a company’s IP is the fact that Singapore has a long-standing and impressive double taxation treaty network with about 60 countries. Coupled with a comparatively low prevailing corporate tax rate of 17%, most businesses find Singapore an excellent location to house IP.

In making a decision regarding whether to remove an IP portfolio from Thailand to a more tax-efficient jurisdiction, it is important to study the potential income streams that the IP holder will receive from potential users/licensors of the IP, as well as the associated tax implications. The issue here is withholding tax. It will be expected that the tax regimes in most jurisdictions will impose withholding tax on the income streams derived from the IP exploitation (as would be the case here in Thailand). Withholding tax will be reduced under double taxation agreements between Singapore and those countries from where the royalties will be paid.

Hong Kong

Unlike offshore financial centers, Hong Kong is not a zero-tax jurisdiction. However, its 17.5% profits tax rate is relatively low compared to the rates of other jurisdictions in Asia.

Hong Kong taxes residents and non-residents only to the extent that they derive Hong Kong–sourced income from the carrying on of trade, profession, or business in Hong Kong. This territorial tax regime provides an opportunity to design the IP holding structure to reduce exposure to Hong Kong profits tax.

Hong Kong’s profits tax system taxes royalty payments received by a Hong Kong company only if (1) the Hong Kong company is considered to carry on trade or business in Hong Kong, and (2) the royalty income is considered to arise in, or be derived from, that Hong Kong trade or business. If properly structured, Hong Kong’s territorial tax regime can provide favorable tax planning opportunities.

Hong Kong generally does not impose withholding tax on outbound payments. But for outbound royalty payments, Hong Kong imposes a withholding tax if the amount paid is treated as income that is chargeable to Hong profits tax under the criteria described above. Otherwise, no withholding tax is imposed.

If withholding tax is chargeable on royalty payments from Hong Kong, the payment would attract a withholding tax of either 5.5% or 17.5%. The higher rate applies if the royalty payment is made to an associate and the intellectual property has been owned, or partly owned, by a person carrying on business in Hong Kong.

Outlook

IP Holding Companies bring together three complex legal fields: (1) IP, (2) tax, and (3) corporate structuring and insolvency. Transactions are cross-border in nature, thus adding to the complexity. But with proper investigation and planning, synergies do arise and IP holding vehicles can offer significant advantages when an IP owner seeks to streamline royalty and licensing intakes from multiple licensees.

RELATED INSIGHTS​ 

July 23, 2025
In cross-border disputes, a recurring concern for claimants is whether they can protect respondents’ assets located in jurisdictions other than the seat of arbitration. This article explores whether Thai courts can issue interim measures, such as freezing orders, under Section 16 of the Thai Arbitration Act (2002) to support an arbitration seated outside of Thailand. Requesting Interim Measures Section 16 provides that a party to an arbitration agreement may request that the court impose interim measures, either before or during arbitral proceedings. If the court determines that it would have been able to impose such measures had the proceedings been conducted in court, it may proceed as requested. Notably, Section 16 does not limit its application to arbitrations seated in Thailand. It simply refers to “a party to an arbitration agreement,” which arguably includes both domestic and international arbitrations. Further, it allows for applications even before arbitration is commenced, provided that the arbitration is initiated within thirty days from the issuance of the order (or other period the court prescribes). A Hypothetical Scenario Consider the following scenario: Company A, incorporated in the Netherlands, and Company B, incorporated in the Cayman Islands, have entered into a contract containing a clause requiring arbitration at the Singapore International Arbitration Center (SIAC). A dispute arises, and Company A commences arbitration at SIAC. Company B holds significant assets in Thailand, such as bank accounts or real estate. Concerned that Company B might dispose of its assets before an award is rendered, Company A applies to the Thai court seeking a freezing order over those assets. Can the Thai court issue such an interim measure? The answer is not straightforward. Thai law is silent regarding whether Section 16 applies to arbitrations seated outside Thailand, leaving the door open for argument. Some academic sources suggest that
July 21, 2025
Distinctiveness is a fundamental requirement for a trademark’s registration and protection under Thai law. The Thai courts typically assess distinctiveness based on a mark’s inherent characteristics rather than its use, as proving acquired distinctiveness through use requires substantial evidence, including the duration of use, extent of distribution and promotional efforts. However, the Intellectual Property and International Trade Court (IP & IT Court) has recently ruled that the figurative mark WEPLAY had acquired distinctiveness through use – an uncommon ruling under Thai trademark law. Subsequently, the Court of Appeal for Specialised Cases affirmed the mark’s inherent distinctiveness based on a holistic assessment of its components. This article discusses the criteria for proving both inherent and acquired distinctiveness, offering examples from both courts to provide valuable insights into case preparation and understanding of how the courts assess distinctiveness. Background In 2017 the plaintiff filed a trademark application for the mark depicted below for goods in Class 28, including toy building blocks: The registrar rejected the application on the grounds of non-distinctiveness under Section 7 of the Trademark Act. The plaintiff appealed to the Board of Trademarks, which considered that, when the term ‘weplay’ is used for goods in Class 28, it is descriptive of the nature of the goods applied for as “playthings”. Therefore, ‘weplay’ was deemed nondistinctive under Section 7, Paragraph 2(2) of the Trademark Act. IP & IT Court decision In 2024 the IP & IT Court ruled that the term ‘weplay’ is not a coined or invented word; instead, it is a combination of ‘we’ and ‘play’, conveying the meaning of ‘we play’. When the term is used for goods in Class 28, it describes the nature of the goods as “playthings”. Consequently, the mark was deemed non-distinctive. However, the court considered the evidence presented by the plaintiff,
July 18, 2025
Vietnam’s electric vehicle (EV) industry is experiencing rapid growth, driven by a strong wave of new legislation, strategic plans, and government incentives. The government’s clear commitment to electrification is attracting foreign investment, supporting advanced production, and reducing reliance on internal combustion engine (ICE) imports. Recent national strategies, sector regulations, and technical standards demonstrate a rare level of regulatory momentum in Southeast Asia, positioning Vietnam as a competitive player in the global EV supply chain and an attractive market for foreign investors. An overview of legal developments for the EV sector in Vietnam is presented below. National Action Program for Green Transportation A key driver of Vietnam’s EV growth has been the National Action Program for Green Transportation through 2050 stipulated in Decision No. 876/QD-TTg of the prime minister dated July 22, 2022. The National Action Program sets a detailed roadmap for the green energy transition in road transport. For the period 2022–2030, the focus is on promoting the manufacturing, assembly, import, and conversion of road motor vehicles to electric power, expanding the use of 100% E5 gasoline for road vehicles, developing charging infrastructure to meet the needs of residents and businesses, and encouraging both new and existing bus stations and rest stops to meet green criteria. For the period 2031–2050, the roadmap aims to gradually restrict and ultimately cease by 2040 the manufacturing, assembly, and import of fossil fuel-powered cars, motorcycles, and mopeds for domestic use. By 2050, the goal is for 100% of road motor vehicles and construction vehicles participating in traffic to use electricity or green energy, for all bus stations and rest stops to meet green criteria, and for all machinery and equipment for loading and unloading to transition from fossil fuels to electricity or green energy. The program also calls for the completion of nationwide
July 14, 2025
Life sciences specialists from Tilleke & Gibbins have updated the firm’s guide to pharmaceutical data exclusivity regulations and practices in Southeast Asia. This guide contains quick-reference information on the availability of data exclusivity protections and limitations in Cambodia, Indonesia, Laos, Malaysia, Myanmar, Thailand, and Vietnam. Developing and launching a new drug on a commercial scale requires an enormous amount of time and investment in research and development (R&D), including pre-clinical testing and clinical trials. When considering the aggregate amount of drug development costs, it is important to recognize that this includes not only the investment in developing new drugs that get approved by a government food and drug regulator and are successfully brought to market, but also the R&D expenditures on a large number of potential pharmaceutical compounds and products that never actually make it to market. In particular, considerable investment is required in order to conduct and produce clinical trial data—to prove safety, efficacy and effectiveness of a new drug—that would warrant marketing approval by the regulatory authority. Such data is proprietary in nature and highly valuable for a research-based pharmaceutical company that develops an original drug. On the other hand, patent law typically confers generic drug manufacturers with the ability to engage in various preparatory activities with a view to obtaining marketing approval for a generic product before the patent for the original drug expires (commonly known as a “Bolar provision”). Since a generic drug maker may submit an application for marketing approval of a generic product before the relevant patent expires, the extent to which the drug originator’s data submitted to the regulatory authority is protected—or in other words, the extent to which the generic company may rely on the drug originator’s previously filed data, which underpins the safety and efficacy of the drug, to support